CD34+ stem cell therapy: Phase III started

Baxter began a double-blind, placebo-controlled, U.S. Phase III trial in about 450 patients to evaluate 10 intramyocardial injections of 0.2 mL CD34+ stem cells. The study includes an unblinded standa...